Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's ....

Primary tabs

field_vote: 
Average: 9 (1 vote)
Publication type: 
Therapeutic intervention: 
References: 

Cancer Biother Radiopharm. 2001 Apr;16(2):171-7.
Cyclophosphamide
plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the
treatment of low-grade non-Hodgkin's lymphomas at advanced stage:
results of a phase II trial.

Todisco M, Casaccia P, Rossi N.
ASL13, Sondrio.

PURPOSE:
Somatostatin, prolactin, retinoids, melatonin and ACTH have been shown
to influence the lymphatic growth, and the action of the
cyclophosphamide in lymphoproliferative disorders is well known. This
provided the rationale to conduct, in patients with low-grade
non-Hodgkin's lymphomas (NHL), a phase II trial of a combined
association of cyclophosphamide, somatostatin, bromocriptin, retinoids,
melatonin and ACTH.
PATIENTS AND METHODS: Twenty patients with a
diagnosis of low-grade NHL, stage III or IV, were included in this
study. Patients received for one month the following treatment:
cyclophosphamide, somatostatin, bromocriptin, retinoids, melatonin, and
ACTH. The therapy was continued for two additional months in patients
with stable or responding disease. After three months, the responding
patients continued the therapy for three months and more.
 
RESULTS:
Twenty patients were assessable for toxicity and response; 70% (14 of
20 patients; 95% confidence interval [CI], 50% to 90%) had a partial
response; 20% (4 of 20) had stable disease, and 10% (2 of 20)
progressed on therapy. Going on with the treatment, none of the 14
patients with partial response had a disease progression (average
follow-up time of 21 months, range, 7 to 25), and 50% of these patients
had a complete response; among 4 patients with stable disease, 25% (1
of 4) had a partial response and 75% (3 of 4) progressed on therapy
(mean time to progression [TTP] 14.3 months, range, 7 to 21). The
toxicity was very mild, the most common side effects being drowsiness,
diarrhea and hyperglycemia.
CONCLUSIONS: The association of
cyclophosphamide, somatostatin, bromocriptin, retinoids, melatonin, and
ACTH is well tolerated and effective in treatment of low-grade NHL at
advanced stage.